Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Nephrology/Urology
Clinical Trials: Prostate Cancer
A listing of clinical trials currently looking for volunteers to enroll in Prostate Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Huntsville : Medical Affiliated Research Center, Inc.
A clinical research study for advanced prostate cancer is currently enrolling
View More »
Birmingham : Teva Investigational Site 100
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Homewood :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Homewood : Urology Centers of Alabama
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Homewood : Urology Center of Alabama
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Muscle Shoals : Investigational Site Number 840002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Muscle Shoals : Investigational Site Number 840004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Alaska
Anchorage : Alaska Clinical Research Center, Llc
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Anchorage :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Anchorage :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Arizona
Phoenix : Precision Trials, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Phoenix : Caris Science, Inc.
EMBRACE1: Prostate Biorepository
Scottsdale : Pinnacle Oncology Hematology
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Scottsdale :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Scottsdale :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
View More »
Tucson :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Tucson : Arizona Cancer Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Tucson :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Arkansas
Fort Smith :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Fort Smith :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Hot Springs : Investigational Site Number 840004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hot Springs : Investigational Site Number 840002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Jonesboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
California
Duarte : City of Hope Updated
A Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Duarte : City of Hope Updated
A Randomized, Phase II Study, Assessing Axitinib as Pre-Surgical Therapy in Patients with High Risk Prostate Cancer
Duarte : City of Hope Updated
Assessment of Change in Peripheral pStat3 Levels, Circulation Tumor Cells and MDSC Quanity in High Risk Prostate Cancer Pre-and Post Prostatectomy
Duarte : City of Hope Updated
Assessment of the Relationship Between Changes in PSA and Peripheral pStat3 Levels, Circulating Tumor Cells, MDSC Quantity and VKOR Mutation in Castrate Resistant Prostate Cancer Patients Receiving Cabazitaxel
Duarte : City of Hope Updated
Assessment of the Relationship Between Changes in PSA and Peripheral pStat3 Levels, MDSC Quantity and VKOR Mutation in Castrate Resistant Prostate Cancer
Duarte : City of Hope Updated
CALGB 90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Duarte : City of Hope Updated
Determination of the Reliability of Expressed Prostatic Secretion and Post Massage Urine Biomarkers in the Detection of Prostate Cancer in Men Undergoing Biopsy for Prostate Cancer
Duarte : City of Hope Updated
Genotypes of Circulating Tumor Cells and Metastases in Prostate Cancer
Duarte : City of Hope Updated
Long Term Follow Up after Prostate Cancer
Duarte : City of Hope Updated
Pre-Surgical EPS Biomarkers as Predictors of Recurrence
Duarte : City of Hope Updated
Prostate Cancer Database
Duarte : City of Hope Updated
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone Sensitive Metastatic Prostate Cancer
View More »
Anaheim : Investigational Site Number 840008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Anaheim : Investigational Site Number 840009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bakersfield : Investigational Site Number 840014
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Beverly Hills : Westside Prostate Cancer Center, University of Southern California
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Escondido : San Diego Radiosurgery at Palomar Medical Center
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer
Fountain Valley :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
La Jolla : University of California San Diego / Moores Cancer Center
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
La Mesa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
La Mesa : Franklin Gaylis, MD, Inc dba Med Research
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Laguna Hills :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Laguna Hills : South Orange County Urology Research
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Laguna Hills : South Orange County Medical Research Center
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Long Beach : VA Medical Center, Long Beach
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Los Angeles :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Los Angeles : Teva Investigational Site 086
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Los Angeles : University of Southern California
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Los Angeles :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Los Angeles : David Geffen School of Medicine at UCLA
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Los Angeles : USC/Norris Comprehensive Cancer Center
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Los Angeles : LAC + USC Medical Center
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Los Angeles : Keck Hospital of USC
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Los Angeles : USC / Norris Comprehensive Cancer Center
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Los Angeles :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Los Angeles :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Marina del Rey : Teva Investigational Site 093
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Marina del Rey :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Modesto : Investigational Site Number 840030
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Orange : Chao Family Comprehensive Cancer Center
Study of Cabazitaxel Plus Bavituximab as Second-line Chemotherapy for Patients With Castration-resistant Prostate Cancer
Orange : Chao Comprehensive Cancer Center
Trail of Taxotere Plus Sunitinib on Newly Diagnosed, Hormone Refractory, Metastatic Prostate Cancer
Oxnard :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Palm Springs : Comprehensive Cancer Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Rancho Mirage : Desert Hematology Oncology
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Riverside :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Sacramento :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Sacramento : University of California at Davis
Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer
San Bernadino : San Bernadino Urological Association
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
San Bernardino : Investigational Site Number 840001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
San Bernardino : Investigational Site Number 840003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
San Diego : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
San Diego : Teva Investigational Site 097
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
San Diego : Southern California Permanente Medical Group
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
San Diego : Sharp Memorial Hospital
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
San Diego :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
San Diego :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
San Francisco : Investigational Site Number 840010 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
San Francisco : Investigational Site Number 840012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
San Francisco : VA Medical Center, San Francisco
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
San Francisco :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
San Francisco : University of California, San Francisco
Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC
San Francisco : Pacific Hematology Oncology Associates
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
San Francisco : UCSF Comprehensive Cancer Center
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
San Luis Obispo : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Santa Monica :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Stanford : Stanford University School of Medicine
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Stockton : Investigational Site Number 840022
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Vallejo : Kaiser Permanente
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
West Los Angeles : VA Greater Los Angeles Healthcare System, West LA
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Colorado
Denver : The Urology Center of Colorado
A Phase II study of Abiraterone Acetate plus Prednisone in subjects with advanced prostate cancer without radiographic evidence of metastatic disease
Denver : The Urology Center of Colorado
A study of Sipuleucel-T with Abiraterone Acetate plus Prednisone in men with metastatic castrate resistant prostate cancer
Denver : The Urology Center of Colorado
Phase II efficacy and safety study of MDV3100 vs. bicalutamide in castrate men with metastatic prostate cancer
Denver : The Urology Center of Colorado
Phase II, Open Label trial studying the sequencing of Sip-T and androgen deprivation therapy in patients with non-metastatic prostate cancer
Denver : The Urology Center of Colorado
Study to Evaluate New or Worsening Lens Opacifications in Subjects with Nonmetastatic
Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy
View More »
Aurora :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Aurora : University of Colorado Hospital
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
Aurora : University of Colorado Cancer Center
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Denver : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Denver : Investigational Site Number 840019
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Denver :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Denver : The Urology Center of Colorado
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Denver :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Connecticut
Middlebury : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New Britain : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Stamford : Investigational Site Number 840021 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Stamford : Investigational Site Number 840029
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Torrington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
View More »
Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
West Haven : VA Connecticut Health Care System (West Haven)
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Florida
Aventura : South Florida Medical Research
Metastatic, Androgen-Independent study for patients with Prostate Cancer
Aventura : South Florida Medical Research, Inc.
Phase IV, Hormone Refractory Prostate Cancer Study
Fort Lauderdale : Holy Cross Hospital
ECOG E3805
Naples : Specialists in Urology
A multicenter clinical study of the Sonablate 500 for the treatment of locally recurrent prostate cancer with HIFU
Tallahassee : Southeastern Research Group, Inc.
Prostate Cancer - A Phase III, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in patients with carcinoma of the prostate with biochemical failure after localized therapy
Tampa : H. Lee Moffitt Cancer Center & Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Aventura :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Aventura : South Florida Medical Research
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Boca Raton : Investigational Site Number 840013
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Boca Raton : Lynn Cancer Institute Center For Hematology-Oncology
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Boynton Beach :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Daytona Beach : Atlantic Urological Associates
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Fort Myers : Teva Investigational Site 106
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Fort Myers :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Fort Myers :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Gainesville : North Florida/South Georgia Veterans Health System
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Gainesville : University Of Florida
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Jacksonville : Investigational Site Number 840019 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Jacksonville : Investigational Site Number 840023 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Jacksonville : Investigational Site Number 840027
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Jacksonville : Investigational Site Number 840035
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Jacksonville : Baptist Cancer Institute
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Lakeland : Investigational Site Number 840013 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Miami Beach : Mount Sinai Comprehensive Cancer Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Ocala : Florida Healthcare Research Urology Center of Florida
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Orange City : Atlantic Urological Associates
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Orlando : Winter Park Urology Associates, PA
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Orlando : Md Anderson Cancer Center Orlando
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Port Saint Lucie :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Port Saint Lucie :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Port St. Lucie : Investigational Site Number 840003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Port St. Lucie : Investigational Site Number 840001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Port St. Lucie : Teva Investigational Site 094
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Port St. Lucie : Hematology Oncology Associates Of The Treasure Coast
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Sarasota : Florida Urology Specialists
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Sarasota :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Trinity : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wellington :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Georgia
Savannah : Memorial Health University Medical Center
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Savannah : Memorial Health University Medical Center
Soy Protein/Isoflavones and Venlafaxine in Treating Hot Flashes in Patients Receiving Hormone Therapy for Prostate Cancer CCCWFU 97405
View More »
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Atlanta :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Atlanta : Teva Investigational Site 096
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Atlanta :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Atlanta : Emory University Winship Cancer Institute
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Atlanta : Georgia Cancer Specialists
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Atlanta : Georgia Cancer Specialists
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Augusta : Georgia Health Sciences University
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Lawrenceville : Suburban Hematology-Oncology Associates, Pc
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Macon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Marietta :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Valdosta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Hawaii
Honolulu : Straub Clinic And Hospital
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Idaho
Coeur d'Alene : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Coeur d'Alene : North Idaho Urology
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Coeur d''Alene :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Meridian :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Meridian : Idaho Urologic Institute
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
View More »
Post Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Illinois
Elgin : Sherman Health
SWOG S1014: Ph II Abiraterone PSA > 4 following initial Androgen Deprivation Tx. M1 dz (visceral dz, distant LN dz &/or bony mets) at time of starting androgen deprivation tx.
Elk Grove Village : Alexian Brothers Hospital Network
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.
View More »
Chicago :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
Chicago : University Of Chicago
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Chicago : Northwestern University Updated
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Decatur : Investigational Site Number 840015
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Decatur : Cancer Care Specialists Of Central Illinois
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Evanston :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Evanston : North Shore University Updated
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Galesburg :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Glenview :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Maywood : Loyola University Chicago
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Melrose Park :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Melrose Park : Uropartners/RMD Clinical Research
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Melrose Park :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Niles : Oncology Specialists, SC
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Niles : Oncology Specialists, S.C
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Park Ridge : Oncology Specialists, S.C.
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Park Ridge : Oncology Specialists, S.C
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Indiana
Carmel : Clarian North Medical Center
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Goshen : Iu Health Goshen Center For Cancer Care
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Greenwood : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Indianapolis : Indiana University School of Medicine
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Indianapolis :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
View More »
Indianapolis :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Jeffersonville :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Jeffersonville : Metropolitan Urology
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Jeffersonville :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Jeffersonville :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Jeffersonville :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Iowa
Cedar Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
West Des Moines : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kansas
Hutchinson : Hutchinson Clinic, Pa
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Overland Park : Kansas City Urology Care, PA
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Topeka : Colmery-O'Neil Va Medical Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Westwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
View More »
Wichita : Investigational Site Number 840018
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Wichita : Cancer Center Of Kansas
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Kentucky
Lexington : University of Kentucky Chandler Medical Center
Cancer: Research Survey Study Needs Men Recently Diagnosed with Prostate Cancer.
View More »
Paducah : Investigational Site Number 840009 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Paducah : Investigational Site Number 840010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Louisiana
Baton Rouge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Baton Rough : Teva Investigational Site 103
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
New Orleans : Investigational Site Number 840007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
New Orleans : Investigational Site Number 840008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
New Orleans :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
View More »
New Orleans :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
New Orleans :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
New Orleans :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Shreveport : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Maine
Scarborough : Maine Center For Cancer Medicine
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Maryland
Annapolis : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Baltimore :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Baltimore : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Baltimore : Johns Hopkins University
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Baltimore : Investigational Site Number 840014 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Baltimore : University Of Maryland
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Baltimore : The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center Updated
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Baltimore : Johns Hopkins Medical Institutions
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Updated
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Baltimore : The Sidney Kommel Comprehensive Cancer at Johns Hopkins
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Baltimore : Chesapeake Urology Research Associates
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Baltimore :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Batlimore : Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bethesda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
Bethesda : Walter Reed National Military Medical Center Updated
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Greenbelt : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Greenbelt : Myron I Murdock, MD, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Rockville : Investigational Site Number 840005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rockville : Investigational Site Number 840006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rockville :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Westminster :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Westminster :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Massachusetts
Boston : Beth-Israel Deaconess Medical Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Boston : Dana-Farber Cancer Institute
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Boston : Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium)
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Boston :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Boston : Beth Israel Deaconess Medical Center
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
View More »
Boston : Dana-Farber Cancer Institute
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Boston : Massachusetts General Hospital
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Boston :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Rockland : Contact US Medical Information in Rockland, MA for US Recruiting Sites
L-BLP25 (Stimuvax) in Prostate Cancer
Watertown : Bay State Clinical Trials, Inc.
Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
Worcester : University of Massachusetts Medical School Updated
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Michigan
Ann Arbor : University of Michigan
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Ann Arbor : Teva Investigational Site 098
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Ann Arbor : University of Michigan Health System
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Ann Arbor : University of Michigan
Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy
Ann Arbor : University of Michigan Health System
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Detroit :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
Detroit : Karmanos Cancer Institute
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Detroit : Investigational Site Number 840005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Detroit : Teva Investigational Site 112
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Detroit : Karmanos Cancer Institute
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Detroit : Wayne State (Karmanos Cancer Institute)
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Detroit :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Lansing :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Minnesota
Rochester : Teva Investigational Site 032
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Rochester : Mayo Clinic
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Sartell : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
St Louis Park : Investigational Site Number 840017 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
St Louis Park : Investigational Site Number 840021
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Mississippi
Jackson : Investigational Site Number 840011 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Jackson : G.V. (Sonny) Montgomery VA Medical Center, Jackson
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Missouri
Columbia :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Jefferson City :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Jefferson City :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Jefferson City :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Kansas City : Investigational Site Number 840016
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Kansas City : VA Medical Center, Kansas City MO
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Kansas City : Kansas City Veterans Affairs Medical Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
St Louis : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
St. Louis :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Montana
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Missoula : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nebraska
Lincoln : Investigational Site Number 840016 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lincoln : Investigational Site Number 840020
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Omaha : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Omaha :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Omaha : Nebraska Cancer Specialists
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Nevada
Las Vegas :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Las Vegas : Nevada Cancer Institute
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Las Vegas : Comprehensive Cancer Centers of Nevada
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Las Vegas :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Las Vegas :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
View More »
Las Vegas :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
New Jersey
Lawrenceville : AdvanceMed Research
A Clinical Research Study for Advanced Prostate Cancer is Currently Enrolling
Lawrenceville : AdvanceMed Research
Do you have Prostate Cancer?
Lawrenceville : AdvanceMed Research
Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate Cancer
Lawrenceville : AdvanceMed Research
Prostate Cancer that requires Hormone therapy.
View More »
Berlin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
East Orange : Department Of Veterans Affairs NJ Health Care System
A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
East Orange : Department of Veterans Affairs NJ Health Care System
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
East Orange : Investigational Site Number 840015 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
East Orange : Investigational Site Number 840017
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Englewood : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Hackensack : John Theurer Cancer Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Hackensack :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Hackensack :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Hamilton :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Lawrenceville :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Lawrenceville : AdvanceMed Research Premier Urology Associates, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Mount Laurel : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
New Brunswick : Cancer Institute of New Jersey
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
New Brunswick : The Cancer Institute of New Jersey Updated
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
New Brunswick : The Cancer Institute of New Jersey
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
New Mexico
Albuquerque : Urology Group of New Mexico
Prostate Cancer with/without bone metastasis
View More »
Albuquerque : Investigational Site Number 840033
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Albuquerque : New Mexico VA Health Care System, Albuquerque
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Albuquerque : University of New Mexico Cancer Center Updated
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
New York
Bronx : Biomedical Research Alliance of New York
Prostate Cancer - Adult Men
Bronx : Biomedical Research Alliance of New York
Prostate Cancer - Adults
Garden City : Advanced Urology Centers of New York, Garden City Central Research Department
For Men with Non-Metastatic Prostate Cancer: A Clinical Trial That Might Interest You
View More »
Albany :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Albany : The Urological Institute of Northeastern New York
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Albany :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Albany : NYOH Albany Cancer Center at Patroon Creek
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Albany : Community Care Physicians, PC
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Albany :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Bronx : Montefiore Medical Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Brooklyn : Brooklyn Urology Research Group
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Brooklyn :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Buffalo :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Buffalo : VA Western New York Healthcare System at Buffalo
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Buffalo :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
East Setauket : North Shore Hematology/Oncology Associates, P.C.
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
East Syracuse :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
East Syracuse :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Garden City : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Garden City :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Goshen : Goshen Medical Associates
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Lake Success : North Shore University Hospital-Monter Cancer Center
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
New York :
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
New York :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
New York : Memorial Sloan-Kettering Cancer Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
New York : Memorial Sloan Kettering Cancer Center
Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
New York : University Urology
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
New York :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
New York : Memorial Sloan-Kettering Cancer Center
Molecular Studies and Clinical Correlations in Human Prostatic Disease
New York : Memorial Sloan Kettering Cancer Center Updated
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
New York : Weill Cornell Medical College
Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
New York : Memorial Sloan-Kettering Cancer Center Updated
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
New York : NYU Cancer Center
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
New York : Memorial Sloan-Kettering Cancer Center
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
New York :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
New York :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
New York : Memorial Sloan-Kettering Cancer Center
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Poughkeepsie :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Poughkeepsie : The Premier Medical Group of the Hudson Valley, PC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Poughkeepsie :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Poughkeepsie : Premier Medical Group of the Hudson Valley
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Poughkeepsie : Premier Medical Group of the Hudson Valley
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Rochester :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Rochester :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Staten Island : Staten Island Urological Research, PC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Staten Island :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Syracuse : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Syracuse : Suny Upstate Medical University
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Tarrytown : Progenics Pharmaceuticals, Inc.
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Tarrytown : Progenics Pharmaceuticals, Inc.
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
North Carolina
Charlotte : USHIFU
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)
Durham : Duke University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Salisbury : PMG Research of Salisbury
Would you like to help develop a new test for the detection of prostate cancer?
Winston-Salem : PMG Research of Winston-Salem
Would you like to help develop a new test for the detection of prostate cancer?
View More »
Chapel Hill :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Concord :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Concord : Carolina Clinical Trials
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Durham :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Durham : Duke Cancer Institute
BKM120 in Metastatic Castration-resistant Prostate Cancer
Durham : Duke Cancer Institute
Pazopanib, Docetaxel, Prednisone Prostate
Durham : Duke University Updated
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Raleigh :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Raleigh : Investigational Site Number 840024 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Raleigh : Investigational Site Number 840036
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Raleigh :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Raleigh : Cancer Centers of North Carolina
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Raleigh :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Raleigh :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Raleigh :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Washington : Investigational Site Number 840011
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Wilmington : PMG Research of Wilmington
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Winston Salem : PMG Research of Winston Salem
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Winston Salem : Timothy S. Collins, Md
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
North Dakota
Ohio
Akron : Investigational Site Number 840020 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Akron : Investigational Site Number 840026
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cincinnati : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Cincinnati : Teva Investigational Site 107
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Cincinnati :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
View More »
Cincinnati :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Cleveland : Investigational Site Number 840023
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cleveland :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Cleveland :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Columbus :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Oklahoma
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Tulsa : Cancer Care Associates
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Oregon
Portland : VA Medical Center, Portland
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Portland : Oregon Health and Science University Cancer Institute
Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC
Portland : Oregon Health And Science University
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Portland : Kaiser Permanente Oncology/Hematology
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Portland : Oregon Health & Science University
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
View More »
Portland : Oregon Health Science University
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Springfield :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Tualatin :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Pennsylvania
Bala Cynwyd :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bala Cynwyd : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Bala Cynwyd : Urologic Consultants of SE PA
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Bethlehem : St Luke'S Hospital And Health Network
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bryn Mawr : Urology Health Specialists, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
View More »
Dunmore : Investigational Site Number 840032
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lancaster :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Lancaster : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lancaster :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Lancaster : Urological Associates
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Lancaster :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Lancaster :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Philadelphia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Philadelphia : Thomas Jefferson University
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Philadelphia :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Philadelphia : Fox Chase Cancer Center Updated
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Philadelphia : Thomas Jefferson University
SOM 230 and Everolimus in Combination for the Treatment of Prostate Cancer
Pittsburgh :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Pittsburgh :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Pittsburgh :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Pittsburgh :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Rhode Island
Pawtucket : Investigational Site Number 840006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Pawtucket : Investigational Site Number 840007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
South Carolina
Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Charleston : Ralph H Johnson VA Medical Center, Charleston
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Charleston :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Columbia :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Greenville : Cancer Centers Of The Carolinas
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
View More »
Greenville :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Greer : Matrix Research, LLC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Myrtle Beach :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Myrtle Beach : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Myrtle Beach : Investigational Site Number 840037
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Myrtle Beach : Teva Investigational Site 102
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Myrtle Beach : Carolina Urologic Research Center
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Myrtle Beach :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Myrtle Beach : Carolina Urologic Research Center
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Myrtle Beach : Carolina Urologic Research Center
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Myrtle Beach : Carolina Urologic Research Center
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Myrtle Beach : Grand Strand Urology
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Tennessee
Bristol : PMG Research of Bristol
Would you like to help develop a new test for the detection of prostate cancer?
Nashville : Sarah Cannon Research Institute
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Chattanooga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Chattanooga : Investigational Site Number 840025 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Chattanooga : Investigational Site Number 840028
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Chattanooga :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Chattanooga :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Germantown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Knoxville : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Nashville :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Nashville : Teva Investigational Site 101
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Nashville : Urology Associates, PC
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Nashville :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Nashville :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Nashville :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Nashville :
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Nashville : Vanderbilt University
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
Texas
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 Private Capsules In Patients
With Incurable, Stage C Or D Adenocarcinoma Of The Prostate
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 Private Capsules In Combination With Total Androgen Blockade In Patients With Adenocarcinoma Of The Prostate
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Prostate
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Prostate
View More »
Amarillo :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Amarillo :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Austin : The Hospital at Westlake Medical Center
Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery
Bedford :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Bedford :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Corpus Christi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Corpus Christi : Investigational Site Number 840012 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Dallas :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Dallas : VA North Texas Health Care System, Dallas
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Dallas : Urology Clinic of North Texas
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Dallas : Baylor University Medical Center
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Dallas :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Dallas :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Denton :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Houston : The University of Texas M D Anderson Cancer Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Houston : UT MD Anderson Cancer Center
Maximum Androgen Depletion
Houston : UT MD Anderson Cancer Center
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Houston : UT MD Anderson Cancer Center
Neoadjuvant Axitinib in Prostate Cancer
Houston : UT MD Anderson Cancer Center Updated
Neoadjuvant Ipilimumab in Prostate Cancer
Houston : UT MD Anderson Cancer Center
Prostate Conformal Cryotherapy
Houston : UT MD Anderson Cancer Center Updated
TKI258 in Castrate Resistant Prostate Cancer
Midland :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Odessa :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Odessa :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
San Antonio : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
San Antonio : VA South Texas Health Care System, San Antonio
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
San Antonio : Teva Investigational Site 116
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
San Antonio : Urology San Antonio Research
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
San Antonio : Urology San Antonio Research, Pa
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
San Antonio : Urology San Antonio Research
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Temple : Scott & White Memorial Hospital And Clinic
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Tyler : Teva Investigational Site 063
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Tyler : Teva Investigational Site 059
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Tyler :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Tyler :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Webster :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Utah
Salt Lake City : VA Salt Lake City Health Care System, Salt Lake City
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Salt Lake City : Salt Lake Research
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Salt Lake City : Utah Cancer Specialists
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Salt Lake City :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Salt Lake City :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Virginia
Bent Mountain : Brabant Research, Incorporated
Natural Supplements and a Special Diet in Eliminating Growth Hormones Made Outside the Body in Patients With Early-Stage Prostate Cancer, Breast Cancer, or Uterine Cancer
Fairfax :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Newport : Teva Investigational Site 047
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Newport News :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Newport News :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
View More »
Norfolk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Norfolk : Teva Investigational Site 104
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Norfolk : Urology of Virginia
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
Norfolk :
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
Norfolk :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Norfolk :
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Richmond : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Salem :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Salem : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Virginia Beach : Urology of Virginia
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Washington
Seattle : University of Washington- Seattle Cancer Care Alliance
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Burien :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Burien : Seattle Urology Research Center
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Everett : Providence Regional Medical Center Everett
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Kennewick :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Poulsbo : Penisula Cancer Center
SpaceOAR System Pivotal Study
Seattle : VA Puget Sound Health Care System, Seattle
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Seattle : Teva Investigational Site 029
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Seattle : VA Puget Sound
I-125 Versus Pd-103 for Medium Risk Prostate Cancer
Seattle : Group Health Cooperative
I-125 Versus Pd-103 for Medium Risk Prostate Cancer
Seattle :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Seattle : Seattle Cancer Care Alliance
Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy
Seattle : Seattle Cancer Care Alliance
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Seattle : Virginia Mason Medical Center
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Seattle : Virginia Mason Hospital
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Seattle : Virginia Mason Medical Center
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
West Virginia
Wisconsin
Madison :
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Madison : University of Wisconsin Carbone Cancer Center
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Madison : University of Wisconsin Carbone Cancer Center
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Madison : University of Wisconsin Cancer Center
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)
Madison : University of Wisconsin Carbone Cancer Center
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
View More »
Madison : University of Wisconsin Carbone Cancer Center
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
Milwaukee :
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Argentina
Buenos Aires : Investigational Site Number 032002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Buenos Aires : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Buenos Aires : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Caba : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Capital Federal : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
View More »
Ciudad Autonoma de Buenos Aires :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Cordoba : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Cordoba : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
La Rioja : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
La Rioja : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Rosario : Investigational Site Number 032001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rosario : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Rosario : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Salta : Investigational Site Number 032003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
San Miguel De Tucuman : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Santa Fe : Investigational Site Number 032004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santa Rosa :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Venado Tuerto :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Australia
Adelaide : Investigational Site Number 036014 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bankstown : Investigational Site Number 036013 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bankstown : Investigational Site Number 036016
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bendigo :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Box Hill :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
View More »
Box Hill : Investigational Site Number 036010 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Box Hill : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Cairns :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Camperdown :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Camperdown : Investigational Site Number 036012 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Camperdown : Investigational Site Number 036008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Coffs Harbour :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Coffs Harbour : Investigational Site Number 036008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Coffs Harbour : Investigational Site Number 036015
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Concord :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Concord : Investigational Site Number 036001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Concord : Investigational Site Number 036001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Darlinghurst : St Vincent's Hospital, Sydney
A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer
Darlinghurst :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
East Bentleigh : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
East Melbourne :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Elizabeth Vale : Investigational Site Number 036015 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Fitzroy : Investigational Site Number 036009 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Fitzroy : Investigational Site Number 036017
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Footscray :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Frankston : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Garran : Investigational Site Number 036007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Geelong :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Heidelberg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Heidelberg : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Heidelberg West : Investigational Site Number 036005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Herston :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Herston : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Herston : Investigational Site Number 036003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Hobart :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Hobart :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Hornsby : Investigational Site Number 036010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kogarah :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Kogarah : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Kogarah, Sydney : Cancer Care Centre, St George Hospital
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers
Kurralta Park :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Kurralta Park : Investigational Site Number 036012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lismore :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Liverpool :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Malvere :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Malvern : Investigational Site Number 036002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
New South Wales :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Parkville :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Parkville : Investigational Site Number 036002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Port Macquarie :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Randwick :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Redcliffe : Redcliffe Hospital
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers
Redcliffe :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Redcliffe :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Richmond :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
South Brisbane :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
South Brisbane : Investigational Site Number 036006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
South Brisbane : Investigational Site Number 036009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Subiaco :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Subiaco : Investigational Site Number 036016 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Subiaco : Investigational Site Number 036011
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Subiaco : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Toowoomba : Radiation Oncology Queensland
PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)
Tweed Heads :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Wahroonga :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Wahroonga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wahroonga : Investigational Site Number 036003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Watarah :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Westmead :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Wodonga : Investigational Site Number 036004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Wodonga : Investigational Site Number 036013
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Wodonga :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Wodonga :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Woodville South :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Austria
Graz :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Linz :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Salzburg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
View More »
Wels : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Wien :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Wien : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Belarus
Minsk : Investigational Site Number 112002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Belgium
Aalst : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aalst : Onze-Lieve-Vrouwziekenhuis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Antwerpen : Investigational Site Number 056007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bonheiden : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bonheiden : Teva Investigational Site 862
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
View More »
Brasschaat : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : Investigational Site Number 056015 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Brussel : Investigational Site Number 056008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Brussels : Teva Investigational Site 860
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Brussels :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Bruxelle : Hôpital Erasme
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bruxelles :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Bruxelles :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bruxelles : Investigational Site Number 056002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bruxelles : Investigational Site Number 056001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bruxelles : Université Catholique de Louvain
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Charleroi : Investigational Site Number 056009 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Edegem : Investigational Site Number 056014 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Edegem : Teva Investigational Site 864
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Edegem :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Eupen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gent :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Gent :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Gent : Investigational Site Number 056003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Gent : Teva Investigational Site 863
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Gent : UZ Gent
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Gent : AZ Maria Middelares
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Ghent : University Hospital Ghent Updated
The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate
Gilly : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Haine-Saint-Paul : Investigational Site Number 056016 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hasselt :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Hasselt : Investigational Site Number 056005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hasselt :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Ieper : Regionaal Ziekenhuis Jan Yperman VZW
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kortijk :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Kortrijk :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Kortrijk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Kortrijk : AZ Groeninge - Campus Sint-Maarten
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kortrijk :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Leuven :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Leuven :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Libramont : Investigational Site Number 056010 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Liege :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Liege :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Liege :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Liège : Investigational Site Number 056013 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Liège : CHU de Liège
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Mechelen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Namur :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Oostende : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : AZ Damiaan
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Ottignies : Investigational Site Number 056011 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Roeselare :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Roeselare : Investigational Site Number 056004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sint-Niklaas : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Turnhout : Investigational Site Number 056006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Verviers : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Yvoir : Investigational Site Number 056012 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bosnia and Herzegovina
Sarajevo : Klinicki Centar Univerziteta Sarajevo - Klinika za gastroenterohepatologiju
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Brazil
Belo Horizonte : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Belo Horizonte - Mg : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Botucatu, Sao Paulo :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Brasilia : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Cachoeiro de Itapemirim - ES :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Curitiba, Parana :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Florianopolis :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Ijui : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Juiz de Fora, Minas Gerais :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Mogi Das Cruzes : Investigational Site Number 076015 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Mogi das Cruzes, Sao Paulo :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Natal, Rio Grande do Norte :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Passo Fundo :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Passo Fundo : Investigational Site Number 076006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Porto Alegre : Investigational Site Number 076002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Porto Alegre : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Porto Alegre, RS :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Rio de Janeiro :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Rio De Janeiro : Investigational Site Number 076010 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Rio De Janeiro : Investigational Site Number 076004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rio de Janeiro : Multi-Imagem and CDPI - Clínica de Diagnóstico por Imagem
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Salvador : Investigational Site Number 076007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Salvador/BA :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Sao Jose Do Rio Preto : Investigational Site Number 076003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076009 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076013 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sao Paulo : Investigational Site Number 076008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Uberlandia : Investigational Site Number 076003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Volta Redonda - RJ :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bulgaria
Pleven :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Plovdiv :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Plovdiv : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Ruse :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Sofia :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Sofia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Varna :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Canada
Toronto, Ontario : Princess Margaret Hospital
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
View More »
Abbotsford : Teva Investigational Site 118
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Abbotsford : Dr. George Vrabec
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Barrie : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Barrie : The Male/Female Health and Research Centre
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Barrie : Euroscope Inc
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Barrie : Site Ref # / Investigator 56450
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Brampton : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brampton : Dr. Stanley Flax
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Brampton : Dr. Jonathan Giddens
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Brampton : Bramalea Medical Centre
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Brampton : Site Ref # / Investigator 54902
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Brampton :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Brampton :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Brantford :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Brantford : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brantford : Brantford Urology Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Brantford : Site Ref # / Investigator 54543
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Burlington : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Burlington : G. Kenneth Jansz Medicine Professional Corporation
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Burlington : Site Ref # / Investigator 57123
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Burlington : Site Ref # / Investigator 54904
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Burlington :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Calgary : Tom Baker Cancer Centre
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Calgary :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Calgary : Teva Investigational Site 002
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Chicoutimi : Site Ref # / Investigator 57032
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Edmonton : Cross Cancer Institute
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Edmonton :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Edmonton :
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
Edmonton : Teva Investigational Site 023
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Edmonton : Cross Cancer Institute
Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences
Edmonton :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Gatineau : Hôpital de Gatineau
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Granby : Site Ref # / Investigator 55512
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Greenfield Park : Investigational Site Number 124002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Greenfield Park : Urology South Shore Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Greenfield Park : Urology South Shore Research
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Greenfield Park : Urology South Shore Research Inc.
Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year
Greenfield Park : Site Ref # / Investigator 56447
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Greenfield Park :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Greenfield Park :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Guelph : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Guelph : Dr. Eric Hirshberg
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Guelph : Site Ref # / Investigator 56452
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Guelph :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Halifax : QEII Health Sciences Center
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Halifax :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Halifax : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Halifax : Teva Investigational Site 028
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Hamilton : Juravinski Cancer Centre at Hamilton Health Sciences
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Hamilton :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Hamilton : Teva Investigational Site 025
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Hamilton : Juravinski Cancer Centre
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Hamilton :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Kelowna : BCCA - Cancer Centre for the Southern Interior
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Kelowna :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Kelowna :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Kelowna : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kelowna : BC Cancer Agency - Centre for Southern Interior
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Kelowna : Southern Interior Medical Research Inc.
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Kelowna : Site Ref # / Investigator 56446
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Kelowna :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Kelowna :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Kingston : Cancer Centre of Southeastern Ontario at Kingston
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Kingston : Teva Investigational Site 108
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Kingston : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Kitchener : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kitchener : Urology Associates/Urologic Medical Research
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Laval : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Laval : Polyclinique Med Concorde
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Laval : Site Ref # / Investigator 54903
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
London : London Regional Cancer Program
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
London :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
London : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
London : Investigational Site Number 124002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
London :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Mississauga : Investigational Site Number 124007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Moncton : Investigational Site Number 124005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Moncton :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Montreal :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Montreal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Montreal : CHUM-Notre- Dame
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Montreal : Hôpital Maisonneuve-Rosemont
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Montreal : Jewish General Hospital
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Montreal : Investigational Site Number 124003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Montreal : Teva Investigational Site 026
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Montreal : Teva Investigational Site 027
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Montreal : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Montreal :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Montreal :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Newmarket :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Newmarket : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Newmarket : Dr. Morrie Liquornik
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Newmarket : Site Ref # / Investigator 54909
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Newmarket :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Newmarket :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
North Bay : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
North Bay : Office of Dr. Bernard Goldfarb
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
North York :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
North York : Toronto Urology Clinical Study Group
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
North York : Site Ref # / Investigator 54908
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Oakville :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Oakville : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Oakville : Dr. Richard Casey
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Oakville : Site Ref # / Investigator 54542
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Oshawa : Investigational Site Number 124001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Oshawa : Teva Investigational Site 091
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Ottawa :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Ottawa : Investigational Site Number 124003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ottawa : Teva Investigational Site 003
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Ottawa :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Owen Sound : Investigational Site Number 124005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Owen Sound : Dr. Todd Webster
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Owen Sound :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Owensound : Site Ref # / Investigator 56449
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Peterborough : Site Ref # / Investigator 56917
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Pointe-Claire : Site Ref # / Investigator 56445
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Pointe-Claire :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Pointe-Claire :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Quebec : Investigational Site Number 124004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Quebec : CHUQ- Hotel-Dieu de Quebec
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
Quebec : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Quebec City :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Regina : Allan Blair Cancer Centre
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Scarborough : Dr. Allan Abramovitch
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Scarborough : Site Ref # / Investigator 54905
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Scarborough :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Sherbrooke :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Sherbrooke : CHUS - Hôpital Fleurimont - Sherbrooke
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Sherbrooke :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Surrey :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Surrey : Teva Investigational Site 007
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Surrey : Andreou Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Surrey : Site Ref # / Investigator 56443
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Surrey :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Toronto : Univ. Health Network-Princess Margaret Hospital
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Toronto :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Toronto : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Toronto : Investigational Site Number 124006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Toronto : Teva Investigational Site 004
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Toronto : Teva Investigational Site 087
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Toronto : Sunnybrook Health Sciences Centre
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Toronto : Site Ref # / Investigator 56451
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto : Site Ref # / Investigator 56444
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto : Site Ref # / Investigator 57762
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Toronto :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Trois-Rivieres : Site Ref # / Investigator 56453
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Trois-Rivières : Centre Hospitalier régional de Trois-Rivières
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Val d'Or : Site Ref # / Investigator 55513
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Vancouver : BCCA - Vancouver Cancer Centre
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Vancouver :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Vancouver :
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
Vancouver : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Vancouver : Teva Investigational Site 001
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Vancouver : BC Cancer Agency - Vancouver Centre
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
Vancouver : Site Ref # / Investigator 56448
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
Victoria :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Victoria :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Victoria : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Victoria : Teva Investigational Site 085
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Victoria : Dr. Steinhoff Clinical Research
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Victoria : Pacific Urologic Research
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Winnipeg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Winnipeg : Teva Investigational Site 024
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Chile
Santiago :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Santiago : Investigational Site Number 152002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santiago : Investigational Site Number 152004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santiago : Investigational Site Number 152005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Santiago : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
View More »
Santiago : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Santiago - Independencia : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Santiago De Chile : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Temuco :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Temuco : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Temuco : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Vi?a Del Mar : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Vina del Mar :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Vina Del Mar : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Viña Del Mar : Investigational Site Number 152001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
China
Beijing :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Guangzhou :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Tianjin :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Colombia
Bogota :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bogota : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bucaramanga : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Cali :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Medellin : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
View More »
Monteria : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Czech Republic
Benesov : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brno : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Brno : Investigational Site Number 203002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Dromenz :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Hradec :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
View More »
Hradec Dralove :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Hradec Kralove : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Jindrichuv Hradec : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kromeriz :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Kromeriz : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kromertz :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Liberec : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Modrice :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Modrive :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Novy Jicin :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Novy Jicin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Novy Jicin : Investigational Site Number 203003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Olomouc : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Olomouc : Investigational Site Number 203001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Praha :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Praha :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Praha 2 :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Praha 2 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Praha 2 : Investigational Site Number 203004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Praha 4 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Praha 5 :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Praha 5 : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Praha 6 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Praha 8 : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Usti nad Labem :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Usti nad Labem : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Zlin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Zlin :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Zlin :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Znojmo : Nemocnice Znojmo
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Denmark
Aalborg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Aalborg : Aalborg Sygehus
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Aalborg : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Aarhus :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Aarhus : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
View More »
Ålborg : Investigational Site Number 208004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Copenhagen :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Fredericia : Fredericia Hospital, Sygehus Lillebaelt
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Frederiksberg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Herlev :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Herlev : Investigational Site Number 208002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Herlev : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Herlev : Herlev Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Herlev : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Holstebro : Holstebro Sygehus
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kobenhavn : Rigshospitalet
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kobenhavn O : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Kobenhavn O : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
København Ø : Investigational Site Number 208001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Odense C : Investigational Site Number 208003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Odense C : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Roskilde :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Viborg : Regionhospitalet Viborg
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Estonia
Tallinn :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Tallinn :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Tallinn :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Tartu :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Finland
Helsinki :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Helsinki : Investigational Site Number 246002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kuopio : Investigational Site Number 246001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Oulu :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Oulu :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
View More »
Seinajoki :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Tampere :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Tampere :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Tampere :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Turku : Investigational Site Number 246003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
France
Aix en Provencence cedex 01 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amiens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Angers :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Angers :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Angers : CHRU Angers
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Angers Cedex 9 : Teva Investigational Site 551
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Athis Mons : Centre Hospitalier d'Athis Mons site Caron
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Aubagne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Avignon :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Avignon : Investigational Site Number 250005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Avignon : Teva Investigational Site 552
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Avignon : Clinique Rhone Durance
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Besançon Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besançon : CHU Saint-Jacques
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Besancon Cedex : Investigational Site Number 250010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bordeaux :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Bordeaux : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bordeaux Cedex : Investigational Site Number 250002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bourg en Bresse : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brive la Gaillarde : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Caen Cedex 05 : Investigational Site Number 250006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cannes :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Carcassonne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Clermont Ferrand : Centre Hospitalier Laennec
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Clermont-Ferrand : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Draguignan Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Evry : Ramsay Sante
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Grenoble : Teva Investigational Site 553
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Hyeres : Investigational Site Number 250008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
La Roche sur Yon :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
La Roche Sur Yon : Investigational Site Number 250001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
La Roche-sur-Yon :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
La Roche-sur-Yon :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
La Roche-sur-Yon Cedex : Teva Investigational Site 555
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Le Mans :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Le Mans :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Longjumeau cedex 1 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lyon :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Lyon : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lyon : Investigational Site Number 250005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lyon : Groupement hospitalier Edouard Herriot
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Lyon :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Lyon :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Lyon Cedex :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Lyon Cedex :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Marseille : Teva Investigational Site 557
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Marseille : CHU Nord
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Marseille : Hopital de la Conception
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Marseille :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Marseille :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Marseille Cedex 9 : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Melun : Polyclinique Saint-Jean
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Mont de Marsan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montauban : Clinique du Pont de Chaume
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Montauban cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montpellier :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Montpellier : Clinique Beausoleil
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nancy : Centre d'Urologie de Nancy
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nanterre : Hôpital Max Fourestier
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nantes Cedex 2 : Investigational Site Number 250002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Nice Cedex 2 : Teva Investigational Site 558
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Nimes : Investigational Site Number 250004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Nîmes : Groupe hospitalo-universitaire Caremeau
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Niort : Centre Hospitalier Georges Renon
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Orléans : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Paris :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Paris : Investigational Site Number 250010 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Paris :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Paris :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Paris Cedex 05 : Investigational Site Number 250003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Paris Cedex 05 : Teva Investigational Site 560
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Paris Cedex 10 : Investigational Site Number 250004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Paris Cedex 15 :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Paris Cedex 15 : Investigational Site Number 250001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Paris Cedex 15 : Teva Investigational Site 559
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Paris Cedex 20 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris Cedex 5 : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Pierre Benite :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Ploemeur : Clinique du Ter
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Pointe A Pitre : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Poitiers : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Poitiers :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Poitiers Cedex : Investigational Site Number 250007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Pontoise : Clinic De L'Europe
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Pontoise Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Prigny : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Investigational Site Number 250009 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Reims : Investigational Site Number 250007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Reims Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rennes :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Rennes :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Rennes : Hopital Pontchaillou
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rouen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Brieuc Cedex : Investigational Site Number 250006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Saint Grégoire cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Herblain :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Saint Herblain Cedex : Teva Investigational Site 561
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Saint Priest en Jarez :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Saint Quentin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint-Priest-en-Jarez Cedex : Teva Investigational Site 562
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Soissons : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Strasbourg cedex :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Suresnes :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Suresnes : Investigational Site Number 250008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Toulon : Clinique Saint Michel
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Toulouse : Teva Investigational Site 563
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Toulouse : Clinique St Jean Languedoc
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Toulouse Cedex : Investigational Site Number 250003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Toulouse Cedex 03 : Investigational Site Number 250011 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tours : Hopital Bretonneau
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Vandoeuvre les Nancy : CHU Brabois
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Vandoeuvre-les-Nancy Cedex : Teva Investigational Site 564
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Vichy cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villejuif :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Villejuif : Investigational Site Number 250001
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Villejuif : Teva Investigational Site 550
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Villejuif : Institut Gustave Roussy
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Villejuif : Institut Gustave Roussy
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Villejuif Cedex : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Villejuif cedex :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Villejuif cedex :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Germany
Aachen : Investigational Site Number 276003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Aachen : Investigational Site Number 276003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Aachen : Teva Investigational Site 607
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Aachen : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Augsburg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Bad Bergzabern : Praxis Dr. Schlichter
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bautzen : Praxis Dr. Markus Hentschel
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Berlin :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Berlin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : Investigational Site Number 276005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Berlin : Teva Investigational Site 609
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Berlin : Teva Investigational Site 613
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Bonn : Praxis Dr. Richter
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Braunschweig :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Braunschweig : Urologie im Schlosscarree
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bremerhaven : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bremerhaven : Praxis Dr. Ahmad Haider
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Chemnitz : Urologie Chemnitz
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Chemnitz : Praxis Dr. Krieger
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dachau : Gemeinschaftspraxis fur Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Darmstadt : Teva Investigational Site 604
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Dinslaken : Klinikpraxis fur Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dresden :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Dresden :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Dresden : Investigational Site Number 276007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Dresden : Teva Investigational Site 612
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Düsseldorf : Investigational Site Number 276004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Düsseldorf : Investigational Site Number 276001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Erlangen : Investigational Site Number 276001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Erlangen : Investigational Site Number 276004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Erlangen : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Freiburg im Breisgau : Clinic SanaFontis
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Greifswald : Teva Investigational Site 618
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Halle/Saale : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hamburg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Hamburg :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Hamburg : Investigational Site Number 276011 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hamburg : Investigational Site Number 276005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Hamburg : Praxis Dr. Schönfelder
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Hannover :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Hannover : Teva Investigational Site 600
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Heidelberg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Heidelberg : Teva Investigational Site 606
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Heidelberg : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Heinsberg : Teva Investigational Site 615
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Homburg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Homburg : Investigational Site Number 276010 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Homburg : Investigational Site Number 276002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Homburg/Saar : Teva Investigational Site 611
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kassel : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kempen : Teva Investigational Site 617
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Kiel : Gemeinschaftspraxis Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kiel : Urologische Gemeinschaftspraxis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kirchheim : Gemeinshaftspraxis Rudolph & Wörner
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Koln :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Koln : Praxis Dr. Thomas Harms
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Leipzig : Vituro
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Mannheim :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Mannheim : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marburg :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Marburg : Teva Investigational Site 608
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Marburg : Praxis Alexander von Keitz
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Marktredwitz : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Meiningen : Teva Investigational Site 616
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Muenchen : Teva Investigational Site 614
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Muenster : Teva Investigational Site 601
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Munchen :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
München : Investigational Site Number 276006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
München : Investigational Site Number 276006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Munich : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Munster :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Munster :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Neunkirchen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nienburg : Praxis Dr. Peczat
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nuertingen : Teva Investigational Site 602
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Nurtingen :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Planneg : Studienzentrum München-Planegg
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Reutlingen : Urologische Gemeinschaftspraxis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rotenburg (Wümme) : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Stralsund : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Stuttgart : Teva Investigational Site 603
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Tostedt : Praxis Dr. Jan Franz
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Tubingen :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Tübingen : Investigational Site Number 276008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tuebingen : Teva Investigational Site 610
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Ulm :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Weiden :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Weiden :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Wesel : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Wuppertal : Investigational Site Number 276002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Wuppertal : Teva Investigational Site 605
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Wuppertal : Praxis fur Urologie
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Greece
Alexandroupoli : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Athens :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Athens : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Athens : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Athens : "Agios Savas" Anticancer-Oncology Hospital of Athens
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Heraklion : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Larissa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Larissa : University Hospital of Larissa
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Patra : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Patras :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Patras :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Patras :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Thessaloniki :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Thessaloniki : Papageorgiou General Hospital of Thessaloniki
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Hungary
Baja : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Baja : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Barcs : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Bekes : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Bekescsaba : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
View More »
Budapest : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Budapest : Investigational Site Number 348004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Budapest : Investigational Site Number 348005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Budapest : Investigational Site Number 348001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Budapest : Teva Investigational Site 691
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Budapest : Teva Investigational Site 694
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Budapest : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Budapest : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Budapest :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Casabai kapu :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Csongrad : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Debrecen : Teva Investigational Site 697
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Debrecen : Teva Investigational Site 692
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Debrecen : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Dunaharaszti : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Dunaujvaros : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Gyor : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Gyor : Teva Investigational Site 696
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Gyor : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Gyula : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Gyula : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Helvecia : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Jaszbereny : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Kaposvar : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Kecskemet : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Kiskunhalas : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Koszarhegy : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Mako : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Miskolc : Teva Investigational Site 698
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Miskolc : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Miskolc : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Miskolc :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Miskolc :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Munkacsy Mihaly :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Nagyvenyim : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Nyiregyhaza : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nyiregyhaza : Teva Investigational Site 699
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Nyiregyhaza : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Nyirpazony : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Oroshaza : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Osztaly :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Osztaly :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Papa : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Pecs : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Pécs : Investigational Site Number 348003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Salgotarjan : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Szeged : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Szeged : Teva Investigational Site 693
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Szeged : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Szekesfehervar : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Szekesfehervar : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Szekszard : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Szentendre : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Szolnok : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Szombathely : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Tiszafoldvar : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Veszprem : Teva Investigational Site 695
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Veszprem : Research Site
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
Ireland
Dublin : Beacon Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dublin : Beaumont Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Galway : University College Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Israel
Beer-Sheva :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Beer-Sheva :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Haifa : Bnai Zion medical center
A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy
Haifa :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Haifa :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Jerusalem :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Jerusalem : Teva Investigational Site 506
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Kfar Saba : Investigational Site Number 376004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Petach Tikva :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Petach Tikva : Teva Investigational Site 505
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Petah Tiqva :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Ramat Gan :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Ramat Gan : Teva Investigational Site 502
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Ramat-Gan :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Tel Aviv : Investigational Site Number 376002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tel Aviv : Teva Investigational Site 503
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Tel Aviv : Ichilov Medical Center
Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy
Tel Hashomer : Sheba Medical Center
Safety Evaluation of ExAblate MRgFUS for Prostate Cancer
Tel-Aviv :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Zerifin :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Zerifin :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Zrifin : Teva Investigational Site 501
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Italy
Arezzo :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Arezzo : Investigational Site Number 380001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Arezzo : Teva Investigational Site 753
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Bari : Investigational Site Number 380004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Catanzaro : Teva Investigational Site 758
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
View More »
Cefalù : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cefalù : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cesena (FC) : Teva Investigational Site 760
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Cremona :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Cremona :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Forli : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Genova : Teva Investigational Site 752
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Lecco :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Lugo (Ravenna) : Teva Investigational Site 755
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Meldola :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Meldola :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Meldola (FC) : Teva Investigational Site 759
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Milano :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Milano : Teva Investigational Site 763
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Milano : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Napoli : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Napoli : Teva Investigational Site 754
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Napoli : Teva Investigational Site 756
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Novara :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Novara :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Orbassano : Investigational Site Number 380003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Padova :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Padova : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ravenna :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Rimini :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Rimini : Teva Investigational Site 761
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Roma :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Roma :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Roma : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roma : Investigational Site Number 380005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Roma : Teva Investigational Site 762
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Roma : Teva Investigational Site 750
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Rome :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Rome :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Rozzano (MI) : Teva Investigational Site 764
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Siena : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Teramo :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Terni : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Torino :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Torino : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Trento : Investigational Site Number 380002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Verona : Teva Investigational Site 765
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Japan
Aichi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Akita : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Arakawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Asahi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Asahikawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
View More »
Ashikaga : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Atsugi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Bunkyo-Ku : Investigational Site Number 392011
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Chiba :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Chigasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Chikushino : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Chubu :
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Chugoku :
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Ebina : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Edogawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Eniwa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Fuji : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Fukuoka :
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Fukuoka :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Fukuoka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Fukuoka-Shi : Investigational Site Number 392021
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Fukushima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Funahashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Habikino : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hakusan : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hamada : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hamamatsu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hamamatsu-Shi : Investigational Site Number 392014
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Hidaka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hirosaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hiroshima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hitachi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Hokkaido :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Hokkaido :
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Houmei : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ibaraki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ibi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ichihara : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ichikawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Iizuka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ikeda : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ikoma : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Inabe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Inuyama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Isahaya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Isesaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Itabashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Itabashi-Ku : Investigational Site Number 392009
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Izumisano : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kahoku : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kaizuka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kanagawa :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Kani : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kansai :
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Kanto :
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Kashiwa-Shi : Investigational Site Number 392001
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Kasuga : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Katsushika : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kawagoe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kawasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kishiwada : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kita Kyushu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kita-Gun : Investigational Site Number 392020
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Kobe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kochi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Koshigaya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Koto-Ku : Investigational Site Number 392002
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Koutou : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kumamoto : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kurashiki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kurobe : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kurume : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kyoto :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Kyoto : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Kyoto-Shi : Investigational Site Number 392016
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Kyoto-Shi : Investigational Site Number 392017
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Kyusyu :
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Maebashi-Shi : Investigational Site Number 392008
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Matsushima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Matsuyama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Minami Satsuma : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Minato-Ku : Investigational Site Number 392012
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Minokamo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Minoo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Mito : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Miyako : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Motiguchi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nagasaki :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Nagasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nagoya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nagoya-Shi : Investigational Site Number 392015
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Nakatsu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nantan : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nara : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Narashino : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Natori : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Neyagawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Niigata :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Niihama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Nirasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Numata : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Ogaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Okayama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Okazaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Osaka :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Osaka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Osaka Sayama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Osaka Sayama-Shi : Investigational Site Number 392019
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Ota : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sagamihara : Research Site
An Open Label Prostate Cancer Study in Japanese Patients
Sagamihara : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Saitama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sakai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sakura : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sapporo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sapporo-Shi : Investigational Site Number 392004
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sasebo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sashima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Seki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sendai : Investigational Site Number 392005
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sendai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Setagaya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shibuya : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shikoku :
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Shimizu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shinagawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shinjuku-Ku : Investigational Site Number 392010
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Shinjyuku : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Shizuoka :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Shizuoka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Suita : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Suita-Shi : Investigational Site Number 392018
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sumida : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sunagawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Sunto-gun : Research Site
An Open Label Prostate Cancer Study in Japanese Patients
Sunto-Gun : Investigational Site Number 392003
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Tachikawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tagajo : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Takaoka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Takarazuka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Takasaki : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tokushima :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Tokushima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tokyo :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Tomakomai : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toride : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toshima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyohashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyonaka : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Toyota : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tsu : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tsubame : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tsuchiura : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Tsukuba-Shi : Investigational Site Number 392007
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Uwajima : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Wakayama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yamagata :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Yamagata : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yamagata-Shi : Investigational Site Number 392006
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Yamaguchi :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Yamato : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yao : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yokohama : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yokohama-Shi : Investigational Site Number 392013
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Yoshinogawa : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yourou : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Yukuhashi : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Zentrsuji : Research Site
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Korea, Republic of
Cheongju,Chungbuk : Teva Investigational Site 404
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Goyang-si Gyeonggi-do : Teva Investigational Site 401
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Gwangju :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Gyeonggi-do :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Jeonnam :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
View More »
Seongnam : Investigational Site Number 410003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seongnam : Seoul National University Bundang Hospital
Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
Seoul :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Seoul :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Seoul : Investigational Site Number 410004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seoul : Investigational Site Number 410005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seoul : Investigational Site Number 410001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seoul : Investigational Site Number 410002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Seoul : Teva Investigational Site 406
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Seoul : Teva Investigational Site 402
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Seoul : Teva Investigational Site 403
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Seoul : Teva Investigational Site 400
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Yangsan-si : Teva Investigational Site 405
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Latvia
Daugavpils :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Daugavpils :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Jelgava : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lieaja :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Liepaja :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Riga :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Riga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Riga :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Lebanon
Beirut :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bsalim :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Lithuania
Kaunas :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Vilnius :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Vilnius :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Malaysia
Kuala Lumpur :
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Mexico
Acapulco : Investigational Site Number 484007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Acapulco : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Aguascalientes : Investigational Site Number 484008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Aguascalientes : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Chihuahua, Chih. :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Cuernavaca : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Culiacan, Sinaloa :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Df : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Distrito Federal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Distrito Federal : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Guadalajara : Investigational Site Number 484004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Guadalajara : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Guadalajara : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Leon, GTO :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Mexico : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Mexico : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Mexico : Local Institution
Study of Immunotherapy to Treat Advanced Prostate Cancer
Mexico City : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Monterrey :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Puebla :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Queretaro : Investigational Site Number 484005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
San Luis Potosi : Investigational Site Number 484002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
San Luis Potosi : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Tlalpan : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Zapopan : Investigational Site Number 484006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Zapopan : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Zapopan, Jalisco :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Netherlands
Amstelveen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amsterdam :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Amsterdam :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Amsterdam : AMC University Amsterdam
BR55 in Prostate Cancer: an Exploratory Clinical Trial
Amsterdam : Teva Investigational Site 851
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
View More »
Amsterdam : Research Site
Open Label Prostate Cancer Study
Amsterdam : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Amsterdam : AMC
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Arnhem : Investigational Site Number 528005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Blaricum : Investigational Site Number 528003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Den Haag : MC Haaglanden
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Dordrecht : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Eindhoven :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Eindhoven : Catharina ziekenhuis
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Eindhoven :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Eindhoven :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Enschede : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groningen :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Groningen :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Groningen : UMC Groningen
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
Hoofddorp : Investigational Site Number 528004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Leiden :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Leiden : Diaconessenhuis Leiden
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Leiderdorp : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nijmegen :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Nijmegen : Investigational Site Number 528002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Nijmegen : UMC Nijmegen
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
Nijmegen : Radboud University Nijmegen Medical Centre
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Purmerend : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Sittard-Geleen : Teva Investigational Site 853
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Sittard-Geleen : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Tilburg :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
TweeSteden ziekenhuis :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Vlissingen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zwolle : Investigational Site Number 528001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
New Zealand
Christchurch :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Christchurch : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Christchurch :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Nelson :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Palmerston North :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Takapuna, North Shore City : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Tauranga :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Tauranga : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Whangarei :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Whangarei : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Norway
Bergen : Haukeland Universitetssykehus
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Gjettum : Vestre Viken HF, Sykehuset Asker og Baerum
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kristiansand : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Oslo : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Oslo : Olso Universitetssykehus HF, Radiumhospitalet
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
View More »
Oslo : Oslo Universitetssykehus, Aker
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Oslo : Jon R Iversen
Treatment of Prostate Cancer With Docetaxel + Hormonal Treatment Versus Hormonal Treatment in Patients Treated With Radical Radiotherapy
Trondheim : Norwegian University of Science and Technology
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Panama
Panama :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Peru
Arequipa :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Arequipa : Investigational Site Number 604003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Lima : Investigational Site Number 604005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lima : Investigational Site Number 604005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Poland
Bialystok :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bialystok : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bielsko-Biala :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Bielsko-Biala :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Bydgoszcz : Investigational Site Number 616002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Gdansk : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Gdansk : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Investigational Site Number 616001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Gdansk : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Gdynia : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Goczalkowice Zdroj :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Goczalkowice-Zdroj :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Katowice :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Katowice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Koscierzyna : Investigational Site Number 616003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Koscierzyna : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Koszalin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Kutno : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Lodz :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Lodz : Investigational Site Number 616005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lubin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lublin : SPSK1 Klinika Hematologii
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Lublin : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Myslowice :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Myslowice :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Myslowice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Olsztyn : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Olsztyn : Investigational Site Number 616002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Opole : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Poznan :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Poznan :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Poznan : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Poznan : Investigational Site Number 616004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Poznan : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Rybnik : Investigational Site Number 616001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Siedlce : Investigational Site Number 616005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Slupsk : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Szczecin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Walbrzych : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warsaw :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Warszawa :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Warszawa : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wolomin :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Wroclaw :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Wroclaw :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Wroclaw : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Wroclaw : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wroclaw :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Wroclaw :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Portugal
Coimbra : Investigational Site Number 620003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lisboa : Investigational Site Number 620004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lisboa : Investigational Site Number 620005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Porto : Investigational Site Number 620001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Porto : Investigational Site Number 620002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Setubal : Investigational Site Number 620006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Romania
Alba Iulia : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Alba Iulia : Investigational Site Number 642005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Baia Mare :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Baia Mare : Investigational Site Number 642006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Baia Mare : Investigational Site Number 642004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Baia-Mare : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasov :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Brasov : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bucharest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Investigational Site Number 642009 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bucuresti : Investigational Site Number 642008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Bucuresti : Investigational Site Number 642005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Bucuresti : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Cluj Napoca : Investigational Site Number 642003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cluj Napoca : Investigational Site Number 642002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Cluj-Napoca :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Cluj-Napoca : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cluj-Napoca, Cluj County : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Constanta :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Craiova :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Focsani : Investigational Site Number 642012 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hunedoara : Investigational Site Number 642007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Hunedoara : Investigational Site Number 642007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Onesti : Investigational Site Number 642013 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Oradea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Piatra Neamt : Investigational Site Number 642011 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ploiesti :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Ramnicu Valcea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Suceava :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Targu Mures : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Timisoara : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara,Timis County : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Russian Federation
Barnaul :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Chelyabinsk : Site Ref # / Investigator 49121
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Ekaterinburg : Investigational Site Number 643009 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Ekaterinburg : Investigational Site Number 643004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Ekaterinburg : Site Ref # / Investigator 49128
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
View More »
Ivanovo : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Izhevsk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Krasnoyarsk : Site Ref # / Investigator 49133
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Moscow :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Moscow :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Moscow : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Moscow : Investigational Site Number 643005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Moscow : Investigational Site Number 643008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Moscow : Site Ref # / Investigator 49103
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Moscow : Site Ref # / Investigator 49105
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Moscow : Site Ref # / Investigator 49107
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Moscow : Site Ref # / Investigator 49108
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Moscow : Site Ref # / Investigator 48905
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Nizhny Novgorod : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Novosibirsk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Obninsk : Investigational Site Number 643008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Omsk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Omsk : Investigational Site Number 643003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Penza : Site Ref # / Investigator 49111
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Pyatigorsk : Investigational Site Number 643002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Rostov-na-Dony : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Rostov-on-Don : Site Ref # / Investigator 49118
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Ryazan : Investigational Site Number 643007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Saratov : Site Ref # / Investigator 49125
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Saratov : Site Ref # / Investigator 49126
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
St. Petersburg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
St. Petersburg :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
St. Petersburg : Site Ref # / Investigator 49112
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
St. Petersburg : Site Ref # / Investigator 49113
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
St. Petersburg : Site Ref # / Investigator 49116
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
St. Petersburg : Site Ref # / Investigator 49109
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
St.Petersburg : Investigational Site Number 643010 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
St.Petersburg : Investigational Site Number 643001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Stavropol : Site Ref # / Investigator 49132
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
St-Petersburg : Investigational Site Number 643005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tomsk : Investigational Site Number 643001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tula : Investigational Site Number 643003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tumen : Site Ref # / Investigator 49129
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Ufa : Site Ref # / Investigator 49120
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Vladimir :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Voronezh : Site Ref # / Investigator 49115
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia
Yaroslavl : Investigational Site Number 643006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Singapore
Singapore :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Singapore :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Slovakia
Banska Bystrica :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Bosany : VEBMED, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bratislava :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Bratislava :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Bratislava : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
View More »
Bratislava : URO clinic, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bratislava : CUIMED, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Bratislava : Univerzitna nemocnica Bratislava
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Galanta : Poliklinika Galanta
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kosice : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Kosice : Univerzitna nemocnica L. Pasteura Kosice
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kosice : MEDICONA s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Kosice - Saca : Nemocnica Kosice - Saca a.s., 1. sukromna nemocnica
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Levice : UROCENTRUM LEVICE, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Malacky : Poliklinika Malacky
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Martin :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Martin : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Martin : Univerzitna nemocnica Martin
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nitra :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Nitra : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Nitra : UROEXAM, spol. s r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Nitra :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Povazska Bystrica : CENTRUM UROLOGIE Povazska Bystrica s.r.o
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Presov :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Presov : MILAB, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Presov :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Sala : UROCENTRUM SALA, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Tenicin :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Topolcany : M & M & M, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Tornala : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Trencin :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Trencin : PRIVATNA UROLOGICKA AMBULANCIA s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Trencin :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Vrable : UROREX, s.r.o.
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Slovenia
Ljubljana : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
South Africa
Cape Town : Investigational Site Number 710003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Durban : Investigational Site Number 710002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
George : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Johannesburg : Investigational Site Number 710004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Johannesburg : Investigational Site Number 710005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Kempton Park : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Paarl : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Paarl : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Port Elizabeth : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Pretoria : Investigational Site Number 710001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tygerberg : Research Site
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Spain
Alcorcon :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Badalona :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Badalona : Investigational Site Number 724003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barcelona :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Barcelona :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
View More »
Barcelona :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Barcelona : Investigational Site Number 724001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barcelona : Investigational Site Number 724001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Barcelona : Investigational Site Number 724002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Barcelona : Investigational Site Number 724007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Barcelona : Teva Investigational Site 803
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Barcelona : Teva Investigational Site 809
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Barcelona : Teva Investigational Site 808
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Barcelona : Hospital Clinic i Provincial de Barcelona
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Barcelona : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Barcelona : Fundación IMOR
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Dos Hermanas : Teva Investigational Site 816
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
El Palmar :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
El Palmar : Teva Investigational Site 814
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Guadalajara : Teva Investigational Site 807
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Hospitalet De Llobregat : Investigational Site Number 724003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
La Coruna :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Madrid :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Madrid : Investigational Site Number 724008 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Madrid : Investigational Site Number 724002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Madrid : Investigational Site Number 724004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Madrid : Investigational Site Number 724005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Madrid : Teva Investigational Site 800
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Madrid : Teva Investigational Site 801
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Madrid : Teva Investigational Site 813
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Madrid : Teva Investigational Site 806
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Madrid : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Málaga : Investigational Site Number 724006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Manresa :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Manresa : Teva Investigational Site 815
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Murcia : Teva Investigational Site 810
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Oviedo :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Palma de Mallorca :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Palma De Mallorca : Investigational Site Number 724005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Palma de Mallorca : Teva Investigational Site 811
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Pamplona :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Pamplona :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Pamplona : Teva Investigational Site 805
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Sabadell :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Sabadell :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Sabadell : Investigational Site Number 724004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sabadell - Barcelona : Teva Investigational Site 804
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
San Sebastian de los Reyes :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Santander :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Santiago De Compostela : Investigational Site Number 724006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Sevilla :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Sevilla : Investigational Site Number 724007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sevilla : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Sevilla :
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Valencia :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Valencia : Teva Investigational Site 802
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Valencia : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Valencia : IVO Instituto Valenciano de Oncología
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Valencia : Private practice, La Cañada, Paterna
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State
Zaragoza :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Sweden
Goteborg :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Göteborg :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Karlstad :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Malmo :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Malmö : Investigational Site Number 752003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
View More »
Malmoe : Urology Dep. Skane Univeristy Hospital
Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer
Orebro :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Stockholm :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Stockholm :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Stockholm : Investigational Site Number 752002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Stockholm : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Umea :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Uppsala : Investigational Site Number 752001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Uppsala : Department of Oncology, University Hospital Uppsala
Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer
Uppsala : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Vaxjo : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Switzerland
Basel : Universitätsspital Basel
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Genolier : IMO Clinique de Genolier
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Lausanne : Centre Hospitalier Universitaire Vaudois
Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer
Zurich : Urozentrum Zürich
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Taiwan
Kaohsiung :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Kaohsiung : Investigational Site Number 158004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Taichung :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Taichung : Investigational Site Number 158002
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Taipei :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Taipei : Investigational Site Number 158001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tao-Yuan : Investigational Site Number 158003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Tunisia
Ariana : Investigational Site Number 788001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sfax : Investigational Site Number 788004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sousse : Investigational Site Number 788003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Tunis : Investigational Site Number 788002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Turkey
Adana : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Ankara :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Antalya : Investigational Site Number 792003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Balcali :
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Bornova : Investigational Site Number 792001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
View More »
Bornova, Izmir : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Gaziantep : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Kayseri : Investigational Site Number 792004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Kocaeli : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Ukraine
Cherkasy : Investigational Site Number 804009
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Chernivtsi :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Dnipropetrovsk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Dnipropetrovsk : Investigational Site Number 804004
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Donetsk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
View More »
Donetsk : Investigational Site Number 804010
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Ivano-Frankivsk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Ivano-Frankivsk : Investigational Site Number 804006
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kharkiv :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Kharkov : Investigational Site Number 804003
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Kyiv :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Kyiv : Investigational Site Number 804001
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Lutsk :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Lutsk : Investigational Site Number 804007
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Simferopol :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Uzhgorod :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Uzhgorod : Investigational Site Number 804005
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Zaporizhzhya :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Zaporizhzhya : Investigational Site Number 804008
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
United Kingdom
Birmingham :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Birmingham : Investigational Site Number 826002 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Birmingham : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Brighton :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Brighton : Teva Investigational Site 704
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
View More »
Bristol :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Cambridge : Teva Investigational Site 701
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Cardiff :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Chichester :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Colchester : Investigational Site Number 826004 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Edinburgh :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Glasgow : Investigational Site Number 826005 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Glasgow : Research Site
Open Label Prostate Cancer Study
Glasgow : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Guildford : Investigational Site Number 826006 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Guildford : Local Institution
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Guildford, Surrey : Teva Investigational Site 705
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Hammersmith : Imperial College Healthcare NHS Trust, Charing Cross Hospital
Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)
Liverpool : Royal Liverpool University Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
London :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
London :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
London : University College London Hospitals
Imaging for Significant Prostate Cancer Risk Evaluation
London : Whipps Cross Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
London : Homerton University Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
London : Royal Marsden NHS Foundation Trust
Prostate Advances in Comparative Evidence
Manchester : Investigational Site Number 826007 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Manchester : Teva Investigational Site 703
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Manchester : Research Site
Open Label Prostate Cancer Study
Merseyside :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Newcastle upon Tyne :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Newcastle Upon Tyne : Investigational Site Number 826003 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Northwood :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Northwood :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Nottingham :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Oxford :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Oxford :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Redhill : East Surrey Hospital
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Rotherham : The Rotherham NHS Foundation Trust - Dept. of Haematology
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Scunthorpe :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Surrey : Teva Investigational Site 700
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Surrey : Research Site
Open Label Prostate Cancer Study
Sutton :
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Sutton :
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Sutton : Investigational Site Number 826001
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Sutton : Investigational Site Number 826001 Updated
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
United States
Washington : George Washington University
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
